^
    17h
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    11d
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    3ms
    TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors. (PubMed, J Immunother Cancer)
    Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.
    Journal
    |
    CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15)
    |
    HCW9218
    3ms
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    3ms
    HCW9218 for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=21, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed | N=60 --> 21
    Trial completion • Enrollment change
    |
    HCW9218
    4ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    4ms
    A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SAR445877
    4ms
    HCW9218 in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Masonic Cancer Center, University of Minnesota | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date
    |
    HCW9218
    4ms
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | N=291 --> 542 | Trial completion date: Nov 2028 --> Jun 2028
    Enrollment change • Trial completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
    5ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    5ms
    ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Terminated, Actym Therapeutics, Inc. | N=35 --> 10 | Trial completion date: Jul 2026 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2025; Sponsor's strategic business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ACTM-838
    5ms
    ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response. (PubMed, Oncotarget)
    Single-cell RNAseq and flow cytometry data confirmed activation and infiltration of both innate and adaptive immune cells. ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • TGFB1 (Transforming Growth Factor Beta 1) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15)
    |
    ACTM-838